Search clinical trials for: SY-5933

Total 80 results

Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation

Advanced Solid Tumor

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

Non-Small Cell Lung Cancer | Solid Tumor | Medullary Thyroid Cancer

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Non-Small Cell Lung Cancer

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Suspended

SY007 in Patients With Acute Ischemic Stroke

Acute Ischemic Stroke

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-009 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects

Health Subjects

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose Incremental Intravenous Injection of SY-007 in Healthy Subjects

Cerebral Apoplexy

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-009 in Healthy Subjects

Diabetes

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-008 in Healthy Subjects

Diabetes

China
Seinda Pharmaceutical Guangzhou Corporation

Completed

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Not yet recruiting

The Efficacy and Safety of Different Doses of SY-009 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes

China
Shouyao Holdings (Beijing) Co. LTD

Not yet recruiting

A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China

Healthy Subjects

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Bellus Health Inc. - a GSK company

Recruiting

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

Healthy | Cough

United Kingdom
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 （Recombinant Human Annexin A5）in Healthy Subjects

Sepsis

China
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Recruiting

SY-005 （Recombinant Human Annexin A5）in Patients With Sepsis

Sepsis

China
Syros Pharmaceuticals

Terminated

A Study of SY-1365 in Adult Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Advanced Solid Tumors

United States, Canada, France
Bellus Health Inc. - a GSK company

Completed

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

Healthy

United Kingdom
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

A Food-drug Interaction Study of SY-004 in Healthy Subjects

Type 2 Diabetes

China
Bellus Health Inc

Completed

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (SOOTHE)

Refractory Chronic Cough

United States, Germany, Canada, Czechia, Hungary, Poland, United Kingdom
Venatorx Pharmaceuticals, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers

Bacterial Infections

United States
IRCCS San Raffaele
Indena S.p.A

Unknown

Safety of Ginkgo Biloba Leaf Extract (GiBiEx)

Healthy

Italy
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

COPD

Belgium
Bellus Health Inc. - a GSK company

Recruiting

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-1)

Refractory Chronic Cough

United States, Canada, Israel, Spain, Belgium, United Kingdom, South Africa, Argentina, Netherlands, Hungary, Colombia, Turkey, Poland, France, India
Bellus Health Inc

Completed

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis (BLUEPRINT)

Atopic Dermatitis | Chronic Pruritus

United States, Canada
Bellus Health Inc

Completed

BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect

Cough

Canada
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Non-small-cell Lung Carcinoma

China
Bellus Health Inc. - a GSK company

Recruiting

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Refractory Chronic Cough

Korea, Republic of, United States, Taiwan, Australia, New Zealand, Czechia, United Kingdom, Germany, Slovakia, India
Bellus Health Inc

Completed

Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

Healthy

United Kingdom
Bellus Health Inc

Terminated

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough (RELIEF)

Chronic Refractory Cough

United States, United Kingdom
Shouyao Holdings (Beijing) Co. LTD

Recruiting

A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors

Advanced Solid Tumor

China
M.D. Anderson Cancer Center

Active, not recruiting

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

Pancreatic Ductal Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | KRAS NP_004976.2:p.G12D

United States
Venatorx Pharmaceuticals, Inc.
National Institutes of Health (NIH)

Completed

VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment

Pharmacokinetics

United States
Sunovion

Completed

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Chiesi Farmaceutici S.p.A.

Completed

2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients (TRIBUTE)

Chronic Obstructive Pulmonary Disease (COPD)

Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Transformed Non-Hodgkin Lymphoma

United States
Millennium Pharmaceuticals, Inc.

Completed

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

Solid Tumors

United States
Black Diamond Therapeutics, Inc.

Recruiting

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Melanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditions

United States
ORIC Pharmaceuticals

Recruiting

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI); ADC Therapeutics S.A.

Recruiting

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive

United States
ARYx Therapeutics

Completed

Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation

Atrial Fibrillation

United States
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

Asthma

Belgium
Yabao Pharmaceutical Group

Completed

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus | Hyperglycaemia (Diabetic)

China
Yabao Pharmaceutical Group

Completed

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

Healthy Volunteers | Hyperglycaemia (Diabetic)

China
Lawson Health Research Institute
London Health Sciences Foundation; Ontario Ministry of Colleges and Universities

Recruiting

Annexin A5 in Patients With Severe COVID-19 Disease (AX-COVID)

Coronavirus Infection | Sepsis

Canada
Pfizer

Completed

ACTiF- Assessment of Closed Tibial Fractures

Tibial Fractures

United States, Australia, Canada, Spain, Turkey, Croatia, India, Bosnia and Herzegovina, Japan, Russian Federation, South Africa

Search clinical trials for: SY-5933

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations